ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

AZN Astrazeneca Plc

11,300.00
50.00 (0.44%)
Last Updated: 09:02:05
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  50.00 0.44% 11,300.00 11,298.00 11,304.00 11,362.00 11,250.00 11,250.00 123,743 09:02:05
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 45.81B 5.96B 3.8415 29.29 174.4B

AstraZeneca's CEO? We Still Don't Know If He's Staying or Going

14/07/2017 11:49pm

Dow Jones News


Astrazeneca (LSE:AZN)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Astrazeneca Charts.
By Chip Cummins 

LONDON -- The mystery surrounding the intentions of the chief executive of AstraZeneca PLC, one of the world's largest pharmaceutical firms, remains...a mystery.

Two days after an Israeli news report said Chief Executive Pascal Soriot had agreed to take the top job at a rival drug giant, Israel-based Teva Pharmaceutical Industries Ltd., AstraZeneca continues to say it won't comment, labeling that report -- and more recent reports that he is staying on -- as market rumors and speculation.

A spokesman late Friday said Dr. Soriot would host the presentation of the company's midyear financial results, expected later this month. But the spokesman declined to say whether that indicated Dr. Soriot was sticking around for the longer term.

A spokesman for Teva said it also wouldn't comment on market rumors.

Shares of AstraZeneca fell sharply Thursday, after an Israeli news site, Calcalist, reported the day before that Dr. Soriot had agreed to take the top job at Teva. They ended London trading down more than 3%. Despite the steep stock market drop, AstraZeneca has repeatedly stopped short of denying the report.

On Friday, shares finished lower for the second day running, falling another 0.29%, amid the uncertainty.

Write to Chip Cummins at chip.cummins@wsj.com

 

(END) Dow Jones Newswires

July 14, 2017 18:34 ET (22:34 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart

Your Recent History

Delayed Upgrade Clock